Literature DB >> 21694815

Exploring the role of monitoring anti-TNFα drug and antibody levels in the management of inflammatory bowel disease.

Allen W Lim1, Remo Panaccione, Cynthia H Seow.   

Abstract

Crohn's disease and ulcerative colitis are chronic inflammatory gastrointestinal disorders which often result in significant morbidity or surgery. Current treatment options are not curative and may cause significant adverse effects. The introduction of anti-tumour necrosis factor alpha (anti-TNFα) therapy over a decade ago was a welcome addition to the therapeutic armamentarium and revolutionized the treatment of inflammatory bowel disease (IBD). Despite their relative success, a significant proportion of patients with IBD fail to respond or subsequently lose response anti-TNFα therapy. This review identifies and explores the role of drug levels and immunogenicity (antibody formation) on the efficacy of anti-TNFα therapy and details how monitoring these parameters may help to optimize the management of patients with IBD.

Entities:  

Keywords:  anti-TNFα; antibodies; inflammatory bowel disease; pharmacokinetics

Year:  2011        PMID： 21694815      PMCID： PMC3105619          DOI： 10.1177/1756283X10382816

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN： 1756-283X            Impact factor:   4.409


  24 in total

Review 1.  Tumor necrosis factor: biology and therapeutic inhibitors.

Authors:  K A Papadakis; S R Targan
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

2.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

Authors:  Richard J Farrell; Mazen Alsahli; Yoon-Tae Jeen; Kenneth R Falchuk; Mark A Peppercorn; Pierre Michetti
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

3.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Authors:  Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

4.  The epidemiology of inflammatory bowel disease in Canada: a population-based study.

Authors:  Charles N Bernstein; Andre Wajda; Lawrence W Svenson; Adrian MacKenzie; Mieke Koehoorn; Maureen Jackson; Richard Fedorak; David Israel; James F Blanchard
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

5.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Authors:  Severine Vermeire; Maja Noman; Gert Van Assche; Filip Baert; Geert D'Haens; Paul Rutgeerts
Journal:  Gut       Date:  2007-01-17       Impact factor: 23.059

6.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors:  Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

7.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

8.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

9.  Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

Authors:  W J Sandborn; S B Hanauer; P Rutgeerts; R N Fedorak; M Lukas; D G MacIntosh; R Panaccione; D Wolf; J D Kent; B Bittle; J Li; P F Pollack
Journal:  Gut       Date:  2007-02-13       Impact factor: 23.059

10.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Authors:  Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682
View more
  2 in total

1.  Curcuma longa extract exerts a myorelaxant effect on the ileum and colon in a mouse experimental colitis model, independent of the anti-inflammatory effect.

Authors:  Rita Aldini; Roberta Budriesi; Giulia Roda; Matteo Micucci; Pierfranco Ioan; Antonia D'Errico-Grigioni; Alessandro Sartini; Elena Guidetti; Margherita Marocchi; Monica Cevenini; Francesca Rosini; Marco Montagnani; Alberto Chiarini; Giuseppe Mazzella
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

2.  Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience.

Authors:  Sami Hoque; Amy Puenpatom; Simona Boccaletti; Chloe Green; Christopher M Black; Jenna Roberts; Ivana Rajkovic; Gary Milligan
Journal:  BMJ Open Gastroenterol       Date:  2020-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.